Hair-cell regeneration & inner-ear gene therapy for Tinnitus: What Does the Evidence Show?
Regenerative Medicine
Current evidence
Gene therapy is genuinely restoring hearing in deaf children — but nothing in the regenerative pipeline measures tinnitus yet.
Evidence strength: Weak (1/5) · Tier 3 — experimental/emerging · Evidence independence: Primarily sponsor-supported.
The long-horizon hope: regrow or repair the damaged inner-ear cells whose loss drives most tinnitus. Includes hair-cell regeneration drugs (FX-322 — failed), gene therapy (DB-OTO, AK-OTOF — succeeding, for congenital deafness), and neural-progenitor cell therapy (Rinri — first-in-human).
Did tinnitus loudness improve?
None shown. No clinical tinnitus data from any regenerative program.
Did tinnitus distress improve?
None shown. Same.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Scored for tinnitus specifically: 1/5 (no data), Tier 3 as a legitimate emerging field to watch.
Has the result been independently replicated?
None yet.
What are the limitations?
- No tinnitus endpoints anywhere in the pipeline
- FX-322's failure shows regeneration in adults is far harder than gene replacement in children
- Whether restoring input reverses established central tinnitus is an open question
What should patients know about safety?
Safety evidence: Not yet assessed. DB-OTO: no therapy-related serious adverse events reported to date.
Is it available?
Regulatory status: Investigational (all programs). DB-OTO (Regeneron): 11 of 12 deaf children gained hearing, 3 to normal thresholds — NEJM 2025; congenital OTOF deafness, not tinnitus. FX-322/FX-345 discontinued Feb 2023 after Phase 2b failure. Rinri's Rincell-1 first-in-human approved by UK MHRA 2025.
Availability: Trials only (specific genetic deafness) · Europe: Trials only · Cost (approx.): N/A
What the studies found
FX-322 (regenerative hair-cell program): Phase 2b failure and program discontinuation
Frequency Therapeutics (company communications) · Company announcement / trade press · 2023 · N=142 (Phase 2b FX-322-208) · Phase 2b randomized placebo-controlled (hearing restoration)
FAILED: no statistically meaningful difference vs placebo on the primary (speech perception) or any secondary endpoint (Feb 2023). Program discontinued; company pivoted away from hearing.
Relevance to tinnitus is INDIRECT: FX-322 targeted hearing restoration, and no tinnitus outcome measure was found in any FX-322 publication or coverage reviewed (the published Phase 1b reported none) — claims that tinnitus was measured are unable-to-verify. The failure matters to the regenerative-medicine pipeline narrative, not to any tinnitus evidence rating.
Cilcare CIL001 tinnitus program (company-reported development)
Cilcare (company communications) · Company announcements / trade press · 2025 · N=— · Drug development program: intratympanic candidate targeting cochlear synaptopathy; Phase 1b/2a program advancing to Phase 2a in chronic tinnitus (US and Europe)
COMPANY-REPORTED ONLY: single intratympanic injection targeting cochlear synaptopathy; Phase 2a in chronic tinnitus planned/underway (2025–26); €40M Series A closed Dec 2024. No peer-reviewed efficacy data exist — every efficacy statement is unverified.
Tracked as pipeline intelligence, not evidence.
Evidence last reviewed: 2026-09-03 · Evidence included through: 2026-09-03 · Confidence: high. Open the interactive evidence profile.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.